Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Horizon Pharma

- PMLiVE

Transparency debate extends to rejected drug applications

Claims from the BMJ made in new published study

- PMLiVE

GSK’s new asthma biologic gains FDA panel backing

British firm looking to help shore up its ageing respiratory portfolio 

- PMLiVE

FDA panel backs Sprout Pharma’s ‘female Viagra’

Could be approved for HSDD in pre-menopausal women

- PMLiVE

IQWiG unimpressed with Tresiba for children

German cost watchdog says Novo’s insulin may in fact cause more harm in certain patients

- PMLiVE

FDA gives priority review for Keytruda in lung cancer

The regulator is expected to deliver a verdict by October 2 

Bristol-Myers Squibb (BMS) building

BMS melanoma combo impresses at ASCO

Increases survival in difficult to treat form of skin cancer

- PMLiVE

FDA approves Pfizer’s new cancer pill

Drug was previously approved as an organ rejection treatment

- PMLiVE

Sanofi pays $245m for FDA priority review voucher

PRV reduces review time from ten to six months

- PMLiVE

FDA approves two new IBS medicines

US regulator gives the nod to Actavis’ and Salix’ bowel drugs

- PMLiVE

Amgen’s immuno-oncology drug scores in skin cancer

Firm hoping its novel treatment will be on the market be the end of this year

- PMLiVE

US lawmakers pass new bill to speed up drug reviews

FDA will also need to take the views of patients into greater consideration under new plans

- PMLiVE

FDA warns of safety concern with SGLT2 inhibitors

Some drugs have been linked to high levels of blood acids

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links